Trade with Eva: Analytics in action >>

Tuesday, March 3, 2020

-=QIAGEN N.V. (QGEN) to be acquired by Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific (TMO) to acquire QIAGEN N.V. in transaction that values QIAGEN at ~$11.5 billion; expected to be immediately accretive
  • The cos have unanimously approved Thermo Fisher's proposal to acquire QIAGEN for 39 per share in cash. The offer price represents a premium of approximately 23% to the closing price of QIAGEN's common stock on the Frankfurt Prime Standard on March 2, 2020, the last trading day prior to the announcement of the transaction. Thermo Fisher will commence a tender offer to acquire all of the ordinary shares of QIAGEN. The transaction values QIAGEN at approximately $11.5 billion at current exchange rates, which includes the assumption of approximately $1.4 billion of net debt.
  • The transaction, which is expected to be completed in the first half of 2021, is subject to the satisfaction of customary closing conditions, including the receipt of applicable regulatory approvals, the adoption of certain resolutions relating to the transaction at an Extraordinary General Meeting of QIAGEN's shareholders, and completion of the tender offer. Thermo Fisher has obtained committed bridge financing. Permanent funding is expected to come from cash on hand and the issuance of new debt. The transaction is not subject to any financing condition.

  • No comments:

    Post a Comment